Email

mingxing.teng@bcm.edu

Positions

Assistant Professor

Department of Pathology & Immunology
Center for Drug Discovery
Baylor College of Medicine

Assistant Professor

Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology
Baylor College of Medicine

Member

Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine

Addresses

Jan and Dan Duncan Neurological Research Institute Building (Office)

Room: N.0670.05 (6th Floor)
Houston, TX, 77030
United States

Education

PhD from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences

07/2015 - Shanghai, China

Postdoctoral Training at Baylor College of Medicine

07/2018 - Houston, Texas, United States

Postdoctoral Training at Dana-Farber Cancer Institute, Harvard Medical School

01/2022 - Boston, Massachusetts, United States

Professional Interests

• Chemical Biology
• Medicinal Chemistry

Websites

Selected Publications

• Miao Q, Kadam VD, Mukherjee A, Tan Z, Teng M.*. " Unlocking DCAFs To Catalyze Degrader Development: An Arena for Innovative Approaches " J. Med. Chem. 2023 Sep ; 66 (19) : 13369-13383.
  Pubmed PMID: 37738232.
• Teng M,* Gray NS.*. " The rise of degrader drugs " Cell Chem. Biol. 2023 Aug ; 30 (8) : 864-878.
  Pubmed PMID: 37494935.
• Teng M, Jiang J, et al. " Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader " Angew. Chem. Int. Ed. Engl. 2023 Apr ; 62 (18) : e202302364.
  Pubmed PMID: 36898968.
• Teng M,* et al. " The Pursuit of Enzyme Activation: A Snapshot of the Gold Rush " J. Med. Chem. 2022 Oct ; 65 (21) : 14289-14304.
  Pubmed PMID: 36265019.
• Teng M, et al. " The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug " J. Med. Chem. 2022 May ; 65 (11) : 7581-7594.
  Pubmed PMID: 35609336.
• Teng M, Lu W, et al. " Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216 " J. Med. Chem. 2022 Jan ; 65 (1) : 747-756.
  Pubmed PMID: 34965125.
• Teng M, Jiang J, Ficarro SB, et al. " Exploring Ligand-Directed N-Acyl-N-alkylsulfonamide-Based Acylation Chemistry for Potential Targeted Degrader Development " ACS Med. Chem. Lett. 2021 Jul ; 12 (8) : 1302-1307.
  Pubmed PMID: 34413960.
• Teng M, et al. " Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface " ACS Med. Chem. Lett. 2020 Apr ; 11 (6) : 1269-1273.
  Pubmed PMID: 32551010.
• Teng M, Jiang J, et al. " Development of CDK2 and CDK5 Dual Degrader TMX-2172 " Angew. Chem. Int. Ed. Engl. 2020 Aug ; 59 (33) : 13865-13870.
  Pubmed PMID: 32415712.
• Teng M, et al. " Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia " Bioorg. Med. Chem. Lett. 2017 Nov ; 27 (22) : 4979-4984.
  Pubmed PMID: 29037948.
• Teng M, et al. " Total synthesis of the monoterpenoid indole alkaloid (±)-aspidophylline A " Angew. Chem. Int. Ed. Engl. 2014 Jan ; 53 (7) : 1814-1817.
  Pubmed PMID: 24481917.

Show 7 more publications

Funding

First-Time Tenure-Track Faculty Recruitment Award
#RR220012

$2,000,000.00   (12/01/2021 - 11/30/2026)

Grant funding from the Cancer Prevention and Research Institute of Texas